Penumbra, Inc. (NYSE: PEN) is a Healthcare company (Medical - Devices) with a market capitalization of $12.6B. The Maz Rating grades it against the other companies in its sector.
Penumbra, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $319.11, Penumbra, Inc. trades at 80.1x trailing earnings, 8.1x sales and 7.9x book value, with an EV/EBITDA of 54.7. Over the last twelve months it generated about $1.6B of revenue and $157M of net income. It runs a gross margin of 68.0%, an operating margin of 12.1% and a net margin of 10.1%. It shows return on equity of 10.4%, return on invested capital of 7.9% and a free cash flow yield of 1.6%. On the balance sheet: a debt-to-equity ratio of 0.13 and a current ratio of 5.89. Over the past 52 weeks the share price ranged from $276.01 to $362.41, with a beta of 0.69.
Penumbra, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 9 Buy and 13 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.